Previous 10 | Next 10 |
Gainers: [[RPHM]] +11.9%. [[BLI]] +6%. [[ARVN]] +5.6%. [[BKEPP]] +3.9%. [[LAKE]] +3.1%.Losers: [[OLED]] -7.2%. [[LMNL]] -5.2%. [[PXLW]] -3.7%. [[FUTU]] -3%. [[AGLE]] -2.3%. For further details see: OLED, FUTU, LAKE and BLI among after-hours movers
Arvinas went public at $16 on September 26, 2018. The stock zoomed to $92.77 on the early trial successes of its two oncology targets. and currently trades at $67.18. Pfizer has a cooperation with Arvinas, which the latter shows may deliver another $802 million potential revenue. ...
NEW HAVEN, Conn., May 20, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that John Houston, Ph.D., President and Chief Executive Officer and Ian Taylor, Ph.D.,...
NEW HAVEN, Conn., May 04, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that it will be leasing three of the 10 floors at 101 College Street in New Haven, Con...
Arvinas (ARVN): Q1 GAAP EPS of -$0.84 misses by $0.04.Revenue of $5.54M (-11.2% Y/Y) beats by $1.45M.Press Release For further details see: Arvinas EPS misses by $0.04, beats on revenue
NEW HAVEN, Conn., May 04, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biopharmaceutical company creating a new class of drugs based on targeted protein degradation, today reported financial results for the first quarter ended March 31, 2021 and provided a corpora...
NEW HAVEN, Conn., April 05, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced two upcoming presentations at the American Association for Cancer Research (AACR) An...
Arvinas (ARVN) shares are poised to rise significantly thanks to a "data-rich" second half of the year, according to Cantor analyst Alethia Young.She is reiterating her overweight rating and is raising her price target to $140 from $121.Based on yesterday's closing price of $58.19, that repre...
Oppenheimer is downgrading shares of Ascendis Pharma (ASND) from outperform to perform and removing its $212 price target.Analyst Leland Gershell says that Street estimates for sales of TransCon hGH (lonapegsomatropin) for pediatric growth hormone deficiency, a BLA for which was submitted las...
The following slide deck was published by Arvinas, Inc. in conjunction with this event. For further details see: Arvina (ARVN) Investor Presentation - Slideshow
News, Short Squeeze, Breakout and More Instantly...
2024-04-12 08:30:02 ET H.C. Wainwright analyst issues BUY recommendation for ARVN on April 12, 2024 06:52AM ET. The previous analyst recommendation was Buy. ARVN was trading at $37.26 at issue of the analyst recommendation. The overall analyst consensus : BUY. Curren...
2024-04-11 13:00:02 ET Bradley Canino from Stifel Nicolaus issued a price target of $72.00 for ARVN on 2024-04-11 09:35:00. The adjusted price target was set to $72.00. At the time of the announcement, ARVN was trading at $38.73. The overall price target consensus is at ...
2024-04-11 11:31:00 ET Arvinas Inc (NASDAQ: ARVN) is in the green at writing after announcing a deal worth over $1.0 billion with Novartis (SWX: NOVN). Details of Arvinas – Novartis agreement Novartis will pay $150 million to the pharmaceutical company up front. In return...